Oral Oncology
Volume 40, Issue 1 , Pages 43-51 , January 2004

Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines

Received 24 April 2003 ,Accepted 27 May 2003.

References 

  1. Hu G, Liu W, Mendelsohn J, et al.  Expression of epidermal growth factor receptor and human papillomavirus E6/E7proteins in cervical carcinoma cells. J Natl Cancer Inst. 1997;89:1271–1276
  2. Iihara K, Shiozaki H, Tahara H, et al.  Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer. 1993;71:2902–2909
  3. Grandis JR, Melhem MF, Gooding WE, et al.  Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–832
  4. Huang S-M, Bock JB, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935–1940
  5. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994;269:27595–27602
  6. Prewett M, Rockwell P, Rockwell RF, et al.  The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996;19:419–427
  7. Ciardiello F, Caputo R, Bianco R, et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053–2063
  8. Nishiwaki Y, Vansteenkiste J, Kudoh S, et al.  A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol. 2003;21:2237–2241
  9. Kris M, Natale RB, Herbst R, et al.  A phase II trial of ZD1839 (‘Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol. 2002;21:292; [abstra 1166]
  10. Cohen EE, Rosen F, Dekker A, et al.  Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol. 2002;21:225; [abstra 899]
  11. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983;1:511–529
  12. Chou JL, Fan Z, DeBlasio T, Koff A, Rosen N, Mendelsohn J. Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat. 1999;55:267–283
  13. Markowitz SD, Molkentin K, Gerbic C, Jackson J, Stellato T, Willson JK. Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. J Clin Invest. 1990;86:356–362
  14. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 1995;95:1897–1905
  15. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996;56:3666–3669
  16. Norbury C, Nurse P. Animal cell cycles and their control. Annu. Rev. Biochem. 1992;61:441–470
  17. Marx J. How cells cycle toward cancer. Science. 1994;263:319–321
  18. Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med. 1989;18:391–395
  19. Jia LQ, Osada M, Ishioka C, et al.  Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog. 1997;19:243–253
  20. Kiyota A, Shintani S, Mihara M, et al.  Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27KIP1 and p15INK4B and induces G1 arrest in oral squamous carcinoma cell lines. Oncology. 2002;63:92–98
  21. Chan KC, Knox F, Gandhi A, Slamon DJ, Potten CS, Bundred NJ. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg. 2001;88:412–418
  22. Di Gennaro E, Barbarino M, Bruzzese F, et al.  Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol. 2003;195:139–150
  23. Choudhury GG. Akt serine threonine kinase regulates platelet-derived growth factor-induced DNA synthesis in glomerular mesangial cells (regulation of c-fos AND p27(kip1) gene expression). J Biol Chem. 2001;276:35636–35643
  24. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakidis TR, Roberts JM. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature. 2001;413:323–327
  25. Montagnoli A, Fiore F, Eytan E, et al.  Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999;13:1181–1189
  26. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49–139
  27. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996;271:20608–20616
  28. Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA. 1998;95:1091–1096
  29. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene. 1997;15:629–637
  30. Loda M, Capodieci P, Mishra R, et al.  Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol. 1996;149:1553–1564
  31. Hoshino R, Chatani Y, Yamori T, et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999;18:813–822
  32. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling (immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms). Am J Pathol. 1998;153:1411–1423

PII: S1368-8375(03)00131-3

doi: 10.1016/S1368-8375(03)00131-3

Oral Oncology
Volume 40, Issue 1 , Pages 43-51 , January 2004

Article Tools

* Image Usage & Resolution